Intelligent Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant

Bio Solutions to Expand U.S. IP Portfolio with Expected Patent Grant

YORK, March 20, 2025 - Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical

technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that it expects to receive its sixth

patent in the United States, which will strengthen the protection of the lateral flow technology core to its Intelligent Fingerprinting

Drug Testing Solution.

expected patent will enhance INBS' existing intellectual property portfolio, which safeguards its unique fingerprint sweat-based

drug screening technology. The anticipated grant will help ensure that the Company's lateral flow technology remains protected

as it advances its U.S. market entry strategy.

our proprietary technology is critical as we plan to scale our footprint in the U.S. drug screening market,"

said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "This

expected patent will further strengthen our portfolio and secure the innovation behind our drug testing solution."

more and more industries prioritise workplace safety and compliance, the demand for smart, efficient, and non-invasive drug testing solutions

continues to rise. INBS' proprietary technology is designed to meet these evolving needs, providing a non-invasive alternative

to traditional drug screening methods. With its innovative sweat-based approach, recent FDA 510(k) submission, and strategic plans to

enter the U.S. market in 2025, INBS is well-positioned to drive industry transformation and expand its global market presence.

details on the patent grant will be announced upon official issuance of the patent.

Intelligent Bio Solutions Inc.

Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering innovative, rapid, non-invasive testing solutions. The Company

believes that its Intelligent Fingerprinting Drug Screening System will revolutionize portable testing through fingerprint sweat analysis,

which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens

for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection

in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The

Company's current customer segments outside the US include construction, manufacturing and engineering, transport and logistics

firms, drug treatment organizations, and coroners.

more information, visit: http://www.ibs.inc

of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section

21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties.

Forward-looking statements in this press release include, without limitation, Intelligent Bio Solutions Inc.'s ability to successfully

develop and commercialize its drug and diagnostic tests, realize commercial benefit from its partnerships and collaborations, and secure

regulatory approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking

statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or

implied by such forward-looking statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology,

including "believes," "estimates," "anticipates," "expects," "plans," "projects,"

"intends," "potential," "may," "could," "might," "will," "should,"

"approximately" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements.

These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, included in Intelligent

Bio Solutions' public filings filed with the Securities and Exchange Commission. Any forward-looking statements contained in this

release speak only as of its date. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained

in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Pinto, Managing Director

Strategic Communications